Data Presented at annual American College of Cardiology (ACC) Scientific Sessions Demonstrates Further Potential of Company's Platform ECM(TM)
CHICAGO and ATLANTA, April 1, 2008 /PRNewswire/ -- CorMatrix Cardiovascular, Inc., an Atlanta-based company dedicated to developing and delivering unique extracellular matrix (ECM(TM)) biomaterial technologies that harness the body's innate ability to repair damaged cardiovascular tissue, presented data on its ECM Technology(TM) this week at the annual American College of Cardiology (ACC) Scientific Sessions in Chicago. Data demonstrated that ECM Technology(TM), in the form of an injectable emulsion, enhanced angiogenesis, increased recruitment of C-kit positive progenitor stem cells, and improved cardiac function in a rat model.
The study, conducted at Emory University, used rats that were subjected to 45 minutes of coronary occlusion, followed by an injection of either the ECM Technology emulsion or a saline control into the affected myocardium and examined at three, seven, 21 and 42 days.
"The animals that received injections of the ECM Technology in an emulsified version demonstrated a significant reversal of cardiac damage and sustained improvements in ejection fraction and overall cardiac function," said Robert Matheny, M.D., Chief Scientific Officer, CorMatrix Cardiovascular, who co-authored the study. "We are very encouraged by this data and intend to continue to analyze the unique remodeling characteristics of the ECM material."
At 42 days post-injection, the population of C-kit positive progenitor
stem cells in the ECM emulsion area and adjacent borders increased a
statistically significant amount relative to the control group, which
received saline injections (32 +/- 0.6 vs. 15 +/- 3.0 per 1000 nuclei).
Enhanced angiogenesis in the ECM Technology emulsion area was also
statistically significant. In addition, echoc
|SOURCE CorMatrix Cardiovascular, Inc.|
Copyright©2008 PR Newswire.
All rights reserved